## **CAMEROON**

#### **BURDEN OF CANCER**



25,876,387

Total # cancer cases (2018)
15,769


Total # cancer deaths (2018)
10,533

Premature deaths from NCDs (2016) 34,330

Cancer as % of NCD premature deaths (2016)

22.4%


## Most common cancer cases (2018)




	8.6%	6.8%	29.3%	1.3%	18.1%	1.0%
PAFS (population attributable fractions)	Tobacco (2017) <sup>a</sup>	Alcohol (2016) <sup>a</sup>	Infections (2012) <sup>b</sup>	Obesity (2012) <sup>b</sup>	UV (2012)°	Occupational risk (2017) <sup>a</sup>
Hactionsy	<sup>a</sup> PAF, cancer deaths	<sup>b</sup> PAF, cancer cases	<sup>c</sup> PAF, melanoma cases			,

### **TRENDS**

#### Estimated past and future trends in total cases per year (breast and lung)




### Probability of premature death from cancer per year




## **INVESTMENT CASE (2019)**

\*Lower middle income



#### Projected lives saved per year



Other childhood cancer

# **CAMEROON**

Availability of population-based cancer	2010	Registration activity	WORKFORCE  **per 10,000 cancer patients  Available staff in Ministry of Health who				
registry (PBCR)**	2007-2016	negistration activity					
Quality of mortality registration***		No coverage	dedicates significant proportion of their time to cancer	2019	yes		
of external beam radiotherapy	2019	0.6	# of radiation oncologist <sup>a</sup>	2019	n/a		
photon, electron) a	2019	0.0	# of medical physicist <sup>a</sup>	2019	n/a		
of mammographs <sup>a</sup>	2020	23.5	# of surgeons <sup>a</sup>	2013	52.		
of CT scanners <sup>a</sup>	2020	17.8	# of radiologist <sup>a</sup>	2019	25.		
of MRI scanners <sup>a</sup>	2020	0.6	# of nuclear medicine physician <sup>a</sup>	2019	n/		
f of PET or PET/CT scanners <sup>a</sup>	2020	0.0	# of medical & pathology lab scientists <sup>a</sup>	2004	n/		
FORMULATING RESPONSE							
ntegrated NCD plan	2019	under development	# Public cancer centres per 10,000 cancer patients	2019	1.3		
ICCP (including cancer types)	2019	under development	Early detection programme/ guidelines for 4 cancers (breast, cervix, colon, childhood)	2019	0 cancer(s		
MPOWER measures fully implemented and schieved	2018	1	Pathology services	2019	generally availabl		
Cancer management guidelines	2019	no	Bone marrow transplantation capacity	2019	generally no availabl		
alliative care included in their operational, ntegrated NCD plan	2019	no	Palliative care availability: community/home-based care	2019	generally no availabl		
of treatment services (surgery, adiotherapy, chemotherapy)	2019	3	Availability of opioids* for pain management	2015-2017			
Breast cancer screening program	2019	no	*Defined daily doses for statistical purposes (S-DDD) per miliion in		per day		
Breast cancer screening program: Starting age, target population	2019	n/a			,		
GLOBAL INITIATIVES							
Elimination of Cervical Cancer			Global Initiative for Childhood Cancer				
HPV vaccination programme coverage	2018	n/a	Annual cancer cases (0-14 years old)	2020	139		
Cervical cancer screening	2019	no	Early detection programme/guidelines	2019	n		
creening programme type	2019	n/a	Defined referral system	2019	n		
creening programme method 2019		n/a					
Screening participation rates 201		n/a	Annual cancer cases (0-14 years old)				
arly detection programme/guidelines 201		n/a no					
	2019		■ Acute lymphoid leukaemi				
Defined referral system	2019	no 98		■ Hodgkin lymphoma			
			45 36 Burkitt lymphoma		t lymphoma		
			56	■ CNS, lo	ow grade tumours		
			921	■ Retino	blastoma		

<sup>\*\*</sup>The incidence estimates for this country have a high degree of uncertainty because they are not based on population based cancer registry
\*\*\*The mortality estimates for this country have a high degree of uncertainty because they are not based on any national NCD mortality data